AbbVie Inc. (TSX:ABBV)
Canada · Delayed Price · Currency is CAD 36.40
-0.21 (-0.57%)
Oct 5, 2026, 11:09 AM EST
AbbVie Revenue
AbbVie had revenue of $16.99B USD in the quarter ending June 30, 2026, with 10.16% growth. This brings the company's revenue in the last twelve months to $64.39B, up 10.39% year-over-year. In the year 2025, AbbVie had annual revenue of $61.16B with 8.57% growth.
Revenue (ttm)
$64.39B
Revenue Growth
+10.39%
P/S Ratio
7.24
Revenue / Employee
$1.13M
Employees
57,000
Market Cap
662.06B CAD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.16B | 4.83B | 8.57% |
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
| Dec 31, 2018 | 32.75B | 4.54B | 16.08% |
| Dec 31, 2017 | 28.22B | 2.58B | 10.06% |
| Dec 31, 2016 | 25.64B | 2.78B | 12.16% |
| Dec 31, 2015 | 22.86B | 2.90B | 14.52% |
| Dec 31, 2014 | 19.96B | 1.17B | 6.23% |
| Dec 31, 2013 | 18.79B | 410.00M | 2.23% |
| Dec 31, 2012 | 18.38B | 936.00M | 5.37% |
| Dec 31, 2011 | 17.44B | 1.81B | 11.55% |
| Dec 31, 2010 | 15.64B | 1.42B | 10.02% |
| Dec 31, 2009 | 14.21B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.20B |
| Extendicare | 1.98B |
| Curaleaf Holdings | 1.87B |
| Green Thumb Industries | 1.72B |
| WELL Health Technologies | 1.52B |
| Sienna Senior Living | 1.08B |
| Knight Therapeutics | 547.31M |
| DRI Healthcare Trust | 285.04M |
AbbVie News
- 2 days ago - AbbVie joins US government pilot to test drug discount rebates - Reuters
- 4 days ago - AbbVie presents long-term RINVOQ data at EADV Congress - TheFly
- 4 days ago - AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo - PRNewsWire
- 4 days ago - AbbVie to Host Third-Quarter 2026 Earnings Conference Call - PRNewsWire
- 5 days ago - AbbVie reports Phase 1 data for ABBV-295 - TheFly
- 5 days ago - AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart - TheFly
- 5 days ago - AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 - PRNewsWire
- 5 days ago - AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 - PRNewsWire